Alembic Pharma gets final USFDA nod for generic version of Arformoterol Tartrate inhalation solution
The approval by the US Food Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial, the company said in a statement.
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Arformoterol Tartrate Inhalation Solution, 15 mcg (base)/2 mL Unit-dose Vial. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Submission Of Notice Of The Meeting Of The Unsecured Creditors Of The Company Convened As Per The Directions Of Hon'Ble National Company Law Tribunal, Ahmedabad Bench ('NCLT')
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Notice convening the meeting of Unsecured Creditors of the Company scheduled to be held on Tuesday, 14th June, 2022 at 1:30 P.M. IST through Video Conferencing / Other Audio Visual Means for the purpose of considering, and if thought fit, approving, with or without modification(s), the proposed Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders ('Scheme'). The said meeting is convened as per the directions of the NCLT vide an Order dated 28th April, 2022 and additional Order dated 9th May, 2022. A copy of the said Notice is uploaded on website of the Company at www.alembicpharmaceuticals.com We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Submission Of Notice Of The Meeting Of The Secured Creditors Of The Company Convened As Per The Directions Of Hon'Ble National Company Law Tribunal, Ahmedabad Bench ('NCLT')
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Notice convening the meeting of Secured Creditors of the Company scheduled to be held on Tuesday, 14th June, 2022 at 12.30 P.M. IST through Video Conferencing / Other Audio Visual Means for the purpose of considering, and if thought fit, approving, with or without modification(s), the proposed Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders ('Scheme'). The said meeting is convened as per the directions of the NCLT vide an Order dated 28th April, 2022 and additional Order dated 9th May, 2022. A copy of the said Notice is uploaded on website of the Company at www.alembicpharmaceuticals.com We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Submission Of Notice Of The Meeting Of The Equity Shareholders Of The Company Convened As Per The Directions Of Hon'Ble National Company Law Tribunal, Ahmedabad Bench ('NCLT')
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Notice convening the meeting of Equity Shareholders of the Company scheduled to be held on Tuesday, 14th June, 2022 at 3.00 P.M. IST through Video Conferencing / Other Audio Visual Means for the purpose of considering, and if thought fit, approving, with or without modification(s), the proposed Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders ('Scheme'). The said meeting is convened as per the directions of the NCLT vide an Order dated 28th April, 2022 and additional Order dated 9th May, 2022. A copy of the said Notice is uploaded on website of the Company at www.alembicpharmaceuticals.com We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
With reference to the captioned matter, please find enclosed herewith the transcript of the Conference Call held on 2nd May, 2022. We request you to kindly take the same on record. Hold Alembic Pharmaceuticals; target of Rs 758: KR Choksey
KR Choksey recommended hold rating on Alembic Pharmaceuticals with a target price of Rs 758 in its research report date May 05, 2022.
Alembic Pharma arm receives final USFDA approval for generic fever blisters drug
The approved ANDA is therapeutically equivalent to the reference listed drug product Abreva Cream, 10 per cent (OTC) of GlaxoSmithKline Consumer Healthcare, the company said. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's wholly owned subsidiary, Aleor Dermaceuticals Limited has received US Food and Drug Administration (USFDA) Final Approval for Docosanol Cream, 10% (OTC). Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
With reference to the captioned matter, this is to inform the exchange that the audio recording has been hosted on the website of the Company and can be accessed at https://alembicpharmaceuticals.com/quarterly-results/ We request you to kindly take the same on record.